Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Breast 3Other hematologic neoplasm 2Dermatologic 2Plasma cell 1Head & Neck 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Paclitaxel 100Trastuzumab 81pembrolizumab 78Fulvestrant 68Cyclophosphamide 66Carboplatin 49Capecitabine 47Docetaxel 45palbociclib 41Lapatinib 40Letrozole 37Doxorubicin 29olaparib 28Taxes 28Nivolumab 25Magnetic Resonance Spectroscopy 25Gemcitabine 25130-nm albumin-bound paclitaxel 25Everolimus 23Biopsy 23ribociclib 22abemaciclib 21Specimen Handling 21Albumin-Bound Paclitaxel 21Cisplatin 20Radiotherapy 19Bevacizumab 19Ado-Trastuzumab Emtansine 19pertuzumab 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Bexarotene × Breast × Clear all
NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

National Cancer Centre, Singapore

Phase 1 Completed
12 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03323658 2023-01-10

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled 12 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT00055991 2013-02-05

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

Baylor Breast Care Center

Phase 1 Completed
87 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡